HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of Carevix™ from the U.S. Food and Drug Administration (FDA). ASPIVIX’s novel Cervical Stabilizer will allow millions of women across the USA access to significantly less painful treatments and IUD insertions.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
Increasing patients’ safety and care in research is vital when preparing and conducting your study. From a HEMEX perspective, we are tackling in this article four important points you should consider during the process.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
Big congratulations to Sedimentum, who has launched a contactless emergency product for Swiss
households: “SAFE-living”, the intelligent fall detection service. An innovative solution that
doesn’t require wearing a bracelet or pressing an emergency button.
This milestone shows the devotion of our QA team to ensuring HEMEX’s high standards and commitment to quality. Achieving this certification was one of the milestones we wished to accomplish in 2022.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
Only six months after closing its seed round of CHF 2.1 million, the successful healthtech start-up closes its pre-series A financing round of CHF 3.3 million. With this new capital, Sedimentum intends to conquer the Swiss B2C market with its intelligent SAFE-living solution.
We’re delighted to announce that our portfolio startup Resistell AG has completed the pilot phase of its clinical Performance Evaluation
Study (PES) with 100% accuracy and at least 7 hours shorter time-to-result (TTR) compared to gold standard methods.